scholarly journals High level of EGF-R expression in carcinomatous skin invasion: Does it reflect the tissue characteristics of the breast carcinoma aggressiveness?

2002 ◽  
Vol 10 (3) ◽  
pp. 111-114
Author(s):  
Zora Neskovic-Konstantinovic ◽  
Dragica Nikolic-Vukosavljevic ◽  
Ksenija Kanjer ◽  
Danica Jovanovic ◽  
Mirjana Brankovic-Magic
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Inflammatory Breast Cancer ◽  
Normal Skin ◽  
Locally Advanced ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Number Of Patients ◽  
Cancer Aggressiveness

Background: The normal function and distribution of EGF-R and its role in breast cancer aggressiveness, prognosis and prediction, have become extremely important in the light of the recently developed methods of EGF-R targeting. In the aim to investigate the relationship between EGF-R and the aggressive tumor behavior, the EGF-R content was analyzed as related to the presence of inflammatory breast skin involvement. Methods: EGF-R, ER and PR content was determined at diagnosis, using the biochemical methods, in the group of 103 unselected breast cancer patients, either in primary tumors (TU), lymph nodes (LN) or skin tissue samples (65, 27 and 11 cases respectively). In 10 patients with inflammatory breast cancers, TU/LN tissue was sampled from 3, and skin from 7 patients. Results: ER and PR content was significantly higher in tumor and LN tissue, compared to the invaded skin the EGF-R content was, on the contrary, significantly higher in skin than in TU or LN tissue. However, no difference was found between TU and LN in all three receptors' content. When the receptor content was analyzed in 10 patients with inflammatory breast cancer, higher levels of both ER and PR were found in tumor biopsies than in skin biopsies, while for the EGF-R the result was opposite. Significantly lower ER content and a trend towards higher EGF-R content was found in the inflammatory breast cancers in comparison to the non-inflammatory ones. Conclusion: Although we examined a small number of patients, our results suggest that the EGF-R could be a marker of breast cancer aggressiveness. However, the influence of the normal skin cells contaminating the biopsied tumor tissue cannot be ruled out. The predictive role of EGF-R deserves to be further investigated especially in locally advanced inflammatory breast cancer patients.

scholarly journals The Effect of External Radiotherapy to the Left Ventricle Systolic Function in Locally Advanced Breast Cancer Patients

2021 ◽  
Vol 8 (11) ◽  
pp. 350-356
Author(s):  
Helmy Fahada ◽  
Desak Agung Suprabawati ◽  
Dyah Erawati
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Left Ventricular ◽  
Advanced Breast ◽  
External Radiation ◽  
Breast Cancer Patients ◽  
Number Of Patients

Background: Locoregional management in breast cancer patients includes surgery and radiation. Radiation increases the risk of the decreasing of cardiac ventricular performance and known as cardiotoxicity. This study aims to analyze the relationship between radiation exposure in locally advanced breast cancer patients with the left ventricular systolic function. Methods: The subjects in this study were patients with locally advanced breast cancer who underwent external radiation therapy after surgery procedure at Dr. Soetomo General Hospital in January 2021 – April 2021. Examination of left ventricular performance parameters was carried out using an invasive method, the transthoracic echocardiography. The performance parameters examined were left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS). Results: A total of 45 patients were recruited in this study. Twenty-two patients (22/45; 48.9%) underwent radiation therapy from the left side and 23 patients (23/45; 51.1%) from the right side. After external radiation, the number of patients with left ventricular dilatation were increased. On the left side, there were 6 patients (6/22; 27.6%) who experienced dilatation compared to before radiation (3 patients), while on the right side of the body there were 8 patients (8/22; 34.8%) who experienced dilatation compared to before radiation (6 patients). There was an increase in the number of patients who experienced a decrease in EFT and EFB after radiation, although the association was not significant. Almost all patients experienced a decrease in GLS values ​​after radiation (44/45; 97.8%). Conclusion: There was an increase in the number of patients with left ventricular dilatation and decrease in EFT and EFB values after external radiation. Decreased GLS values ​​were found in almost all patients who underwent external radiation in this study. Keywords: Radiation, locally advanced breast cancer, LVID, ejection fraction, GLS.

scholarly journals Racial and Socioeconomic Disparities Are More Pronounced in Inflammatory Breast Cancer Than Other Breast Cancers

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Ryan A. Denu ◽  
John M. Hampton ◽  
Adam Currey ◽  
Roger T. Anderson ◽  
Rosemary D. Cress ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Inflammatory Breast Cancer ◽  
Urban Areas ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Breast Cancer Patients ◽  
Cancer Specific Survival ◽  
Cancer Data ◽  
Patterns Of Care Study

Inflammatory breast cancer (IBC) is a rare yet aggressive form of breast cancer. We examined differences in patient demographics and outcomes in IBC compared to locally advanced breast cancer (LABC) and all other breast cancer patients from the Breast and Prostate Cancer Data Quality and Patterns of Care Study (POC-BP), containing information from cancer registries in seven states. Out of 7,624 cases of invasive carcinoma, IBC and LABC accounted for 2.2% (N=170) and 4.9% (N=375), respectively. IBC patients were more likely to have a higher number (P=0.03) and severity (P=0.01) of comorbidities than other breast cancer patients. Among IBC patients, a higher percentage of patients with metastatic disease versus nonmetastatic disease were black, on Medicaid, and from areas of higher poverty and more urban areas. Black and Hispanic IBC patients had worse overall and breast cancer-specific survival than white patients; moreover, IBC patients with Medicaid, patients from urban areas, and patients from areas of higher poverty and lower education had worse outcomes. These data highlight the effects of disparities in race and socioeconomic status on the incidence of IBC as well as IBC outcomes. Further work is needed to reveal the causes behind these disparities and methods to improve IBC outcomes.

Efficacy and safety of neoadjuvant chemotherapy of sequential doublets and dose dense plus trastuzumab in HER2-positive locally advanced breast cancer patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 11089-11089
Author(s):  
E. Grande ◽  
A. Sanchez-Muñoz ◽  
A. García-Tapiador ◽  
A. Ortega-Granados ◽  
A. Jaén-Morago ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Cancer Patients ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Chemotherapeutic Agents ◽  
Advanced Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Number Of Patients

11089 Background: Neoadjuvant therapy for breast cancer constitutes an excellent test to evaluate the sensitivity to chemotherapeutic agents and/or new biological agents against specific targets as trastuzumab and Her2. Furthermore, pathologic complete response (pCR) is a surrogate marker for disease-free and overall survival. Methods: The objective was to determine the efficacy in terms of pCR rates and the safety profile of the doublets plus trastuzumab schedule administered for the neoadjuvant setting of locally advanced breast cancer patients. A total of 20 patients with histologically confirmed locally invasive Her2-positive breast carcinoma were included. The median age was 43. Mean tumour size was 5.1 cm. Treatment consisted of a first sequence with epirubicin 90 mg/m2 and cyclophophamide 600 mg/m2 for 3 cycles, and a second sequence with paclitaxel 150 mg/m2 and gemcitabine 2500 mg/m2 for six cycles. All drugs were administered on day 1, every two weeks with prophylactic growth factor supports. Weekly trastuzumab was administered at a dose of 2mg/kg (4 mg/kg loading dose), concomitantly with paclitaxel and gemcitabine. Subsequently, patients underwent surgery and received radiotherapy and/or adjuvant hormonal therapy according to institutional practice Results: Objective clinical response was achieved in all patients. 10 (50%) pCR were obtained. With a median follow up of 18.2 months (3–38), 17 patients (85%) are alive without disease progression, and 3 (15%) showed recurrence and 1 of whom died. Treatment was well tolerated, 1 patient experienced 1 episode of grade 4 neutropenia and 2 patients had grade 3 neutropenia. 1 patient discontinued the treatment due to hypersensitivity reaction to paclitaxel. Asymptomatic decrease in cardiac ejection fraction with subsequent normalization was seen in 1 case. Conclusions: Despite of the small number of patients, results have shown a high pCR rate in this group of breast cancer patients with poor prognostic. The schedule seems to be feasible and tolerable and further studies with the doublet sequences plus trastuzumab are warranted on the neoadjuvant Her2 positive breast cancer patients No significant financial relationships to disclose.

scholarly journals Frequency locally advanced and metastatic breast cancer at the time of presentation in a private hospital in Peshawar.

2019 ◽  
Vol 26 (10) ◽  
pp. 1693-1696
Author(s):  
Amjad Ali
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Disease ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Late Presentation ◽  
Hard Copy ◽  
Medical Institute ◽  
Breast Cancers ◽  
Breast Cancer Patients

Breast cancer is the most common cancer among women and Pakistan has the highest rate of breast cancers in Asia. Breast cancer patients present very late with their symptoms in Pakistan as compared to the developed world. As a result, our survival outcomes are very poor. To estimate the frequency of breast cancer patients presenting with locally advanced and metastatic disease at presentation at our dedicated one-stop breast care unit (BCU) at Rehman Medical Institute Peshawar. Study Design: Observational study. Setting: Rehman Medical Institute Peshawar. Period: 1st January 2018 to 31st December 2018. Material and Methods: Data was prospectively collected of all breast cancer patients presenting to BCU and recorded both electronically and in hard copy, and analysed. Results: A total of 83 patients were identified. 30% of the patients had metastatic disease at presentation while 34% had locally advanced disease. Only 36% had early breast cancer. Conclusion: This study supported the previously reported trend of very late presentation of patients with breast cancer in Pakistan.

Analysis of AKR1B10 levels among various groups of breast cancer patients.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14548-e14548
Author(s):  
Krishna A. Rao ◽  
Kathy Robinson ◽  
Kristin Delfino ◽  
Vivekanand Tiwari ◽  
Yun Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Locally Advanced ◽  
Elevated Serum ◽  
Metastatic Breast ◽  
Oncotype Dx ◽  
Breast Cancer Patients ◽  
Serum Samples ◽  
Primary Tumors

e14548 Background: Aldo-keto reductase 1B10 (AKR1B10) is a protein that is primarily expressed in human colon and small intestine, but induced in hepatocellular carcinoma and non-small cell lung cancer. Our recent studies have revealed that AKR1B10 is overexpressed in primary, metastatic, and recurrent cancers of the breast. Methods: We recruited four cohorts of patients: Patients with breast cancer undergoing primary surgery from whom we procured breast cancer and matched normal adjacent tissue to evaluate AKR1B10 expression in primary tumors. The matched serum samples were collected before surgery and at various time points after the surgery (approximately 3 days, 7 days, and 1 month Patients with recurrent or advanced (metastatic) breast cancer. Serum samples were collected and serially monitored for up to 2years before and during metastatic therapy and correlated with RECIST measurements. Patients with locally advanced disease undergoing neoadjuvant chemotherapy. AKR1B10 serum levels were monitored during therapy and correlated with RECIST measurements. Healthy individuals with normal mammograms were recruited and submitted serum samples for AKR1B10 serum measurements. Results: AKR1B10 rapidly cleared the serum of early stage breast cancer patients with an estimated half-life of 24-30 hours. Serum AKR1B10 levels correlated strongly with tissue IHC staining and PR positivity but not with RECIST levels or Oncotype Dx scores. Neoadjuvant chemotherapy did not affect serum AKR1B10 levels. Individuals with normal mammograms displayed substantially lower levels of AKR1B10 than breast cancer patients. Patients with DCIS also displayed elevated serum AKR1B10 levels. Conclusions: AKR10 may serve as tumor marker to independently identify high risk patients whose tumors have intermediated risk Oncotype Dx scores and may also identify early breast cancers in patients with equivocal breast biopsies.

Long-Term Follow-Up for Locally Advanced and Inflammatory Breast Cancer Patients Treated With Multimodality Therapy

2004 ◽  
Vol 22 (20) ◽  
pp. 4067-4074 ◽  
Author(s):  
Jennifer A. Low ◽  
Arlene W. Berman ◽  
Seth M. Steinberg ◽  
David N. Danforth ◽  
Marc E. Lippman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Inflammatory Breast Cancer ◽  
Locally Advanced ◽  
Stage Iii ◽  
Breast Cancer Patients ◽  
Stage Iiia ◽  
Stage Iii Breast Cancer

Purpose To determine long-term event-free (EFS) and overall survival (OS) for patients with stage III breast cancer treated with combined-modality therapy. Patients and Methods Between 1980 and 1988, 107 patients with stage III breast cancer were prospectively enrolled for study at the National Cancer Institute and stratified by whether or not they had features of inflammatory breast cancer (IBC). Patients were treated to best response with cyclophosphamide, doxorubicin, methotrexate, fluorouracil, leucovorin, and hormonal synchronization with conjugated estrogens and tamoxifen. Patients with pathologic complete response received definitive radiotherapy to the breast and axilla, whereas patients with residual disease underwent mastectomy, lymph node dissection, and radiotherapy. All patients underwent six additional cycles of adjuvant chemotherapy. Results OS and EFS were obtained with a median live patient follow-up time of 16.8 years. The 46 IBC patients had a median OS of 3.8 years and EFS of 2.3 years, compared with 12.2 and 9.0 years, respectively, in stage IIIA breast cancer patients. Fifteen-year OS survival was 20% for IBC versus 50% for stage IIIA patients and 23% for stage IIIB non-IBC. Pathologic response was not associated with improved survival for stage IIIA or IBC patients. Presence of dermal lymphatic invasion did not change the probability of survival in clinical IBC patients. Conclusion Fifteen-year follow-up of stage IIIA and inflammatory breast cancer is rarely reported; IBC patients have a poor long-term outlook.

scholarly journals Activation of nuclear factor-κ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients

2006 ◽  
Vol 13 (2) ◽  
pp. 607-616 ◽  
Author(s):  
C Montagut ◽  
I Tusquets ◽  
B Ferrer ◽  
J M Corominas ◽  
B Bellosillo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Patients ◽  
Response Rate ◽  
Locally Advanced ◽  
Nuclear Staining ◽  
Nuclear Factor ◽  
Breast Cancer Patients ◽  
Number Of Patients ◽  
Pre Treatment

The nuclear factor (NF)-κB system is a promising anticancer target due to its role in oncogenesis and chemoresistance in preclinical models. To provide evidence in a clinical setting on the role of NF-κB in breast cancer, we aimed to study the value of basal NF-κB/p65 in predicting resistance to neoadjuvant chemotherapy, and to characterise the pharmacodynamic changes in NF-κB/p65 expression following chemotherapy in patients with locally advanced breast cancer. Pre- and post-chemotherapy tumour specimens from 51 breast cancer patients treated with anthracycline- and/or taxane-containing neoadjuvant chemotherapy were assayed by immunohistochemistry for NF-κB/p65 subcellular expression. We studied NF-κB/p65, a well-characterised member of the NF-κB family that undergoes nuclear translocation when NF-κB is activated. Activation of NF-κB (i.e. nuclear NF-κB/p65 staining in pre-therapy specimens) was linked to chemoresistance. Patients with NF-κB/p65 nuclear staining in pre-treatment samples had a 20% clinical response rate, while patients with undetected nuclear staining had a 91% response rate to chemotherapy (P = 0.002). Notably, four patients achieved a complete histological response and none of them had pre-treatment NF-κB/p65 nuclear staining. Moreover, the number of patients with NF-κB/p65 activation increased after chemotherapy exposure. It is concluded that NF-κB/p65 activation assayed by immunohistochemistry is a predictive factor of resistance to neoadjuvant chemotherapy in breast cancer patients. Moreover, NF-κB activation was inducible following chemotherapy in a proportion of breast cancer patients. These novel clinical findings strengthen the rationale for the use of NF-κB inhibitors to prevent or overcome chemoresistance in breast cancer.

Sign in / Sign up

Export Citation Format

Share Document